FY2026 Earnings Forecast for Insmed Issued By HC Wainwright

Insmed, Inc. (NASDAQ:INSM) – Equities researchers at HC Wainwright issued their FY2026 EPS estimates for shares of Insmed in a note issued to investors on Wednesday, November 4th. HC Wainwright analyst M. Caufield forecasts that the biopharmaceutical company will post earnings of ($1.81) per share for the year. HC Wainwright currently has a “Buy” rating and a $220.00 price target on the stock. The consensus estimate for Insmed’s current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for Insmed’s Q4 2026 earnings at ($0.29) EPS, FY2027 earnings at $1.13 EPS, FY2028 earnings at $3.15 EPS, FY2029 earnings at $5.25 EPS and FY2030 earnings at $10.77 EPS.

Other research analysts also recently issued reports about the stock. Wells Fargo & Company upped their price target on shares of Insmed from $161.00 to $169.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Bank of America reiterated a “buy” rating and issued a $207.00 price target on shares of Insmed in a research note on Monday, October 12th. The Goldman Sachs Group started coverage on Insmed in a report on Thursday, September 24th. They set a “buy” rating and a $188.00 price objective on the stock. Raymond James Financial set a $173.00 price objective on Insmed in a research report on Tuesday, October 20th. Finally, Mizuho set a $154.00 target price on Insmed in a report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $196.52.

Insmed Trading Down 1.1%

Shares of Insmed stock opened at $108.76 on Friday. Insmed has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86. The company’s 50 day moving average price is $111.35 and its two-hundred day moving average price is $124.61.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The company had revenue of $524.43 million for the quarter, compared to analyst estimates of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. Insmed’s revenue for the quarter was up 268.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.75) earnings per share.

Institutional Trading of Insmed

Several institutional investors have recently modified their holdings of the business. Private Advisor Group LLC increased its holdings in Insmed by 1.8% in the first quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company’s stock valued at $777,000 after purchasing an additional 82 shares during the period. Glenmede Trust Co. NA raised its position in Insmed by 5.4% during the 1st quarter. Glenmede Trust Co. NA now owns 1,916 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 98 shares during the last quarter. Waldron Private Wealth LLC lifted its holdings in Insmed by 1.1% during the 3rd quarter. Waldron Private Wealth LLC now owns 8,910 shares of the biopharmaceutical company’s stock worth $1,017,000 after buying an additional 100 shares during the period. Parallel Advisors LLC lifted its holdings in Insmed by 5.4% during the 3rd quarter. Parallel Advisors LLC now owns 2,275 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 117 shares during the period. Finally, Yousif Capital Management LLC lifted its holdings in Insmed by 4.7% during the 3rd quarter. Yousif Capital Management LLC now owns 2,993 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 134 shares during the period.

Insider Activity at Insmed

In other Insmed news, Director David R. Brennan sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the transaction, the director directly owned 39,238 shares in the company, valued at approximately $4,865,512. This represents a 38.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Roger Adsett sold 239,850 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the transaction, the chief operating officer owned 98,744 shares of the company’s stock, valued at approximately $13,159,612.88. This trade represents a 70.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by company insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.